首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 基因療法

市場調查報告書

商品編碼

1907938

AAV基因治療市場按載體血清型、治療領域、目標組織、適應症類型、基因有效載荷類型、研發階段、生產類型、最終用戶和地區分類

AAV Gene Therapy Market, By Vector Serotype, By Therapeutic Area, By Target Tissue, By Indication Type, By Gene Payload Type, By Development Stage, By Manufacturing Type, By End User, By Geography

出版日期: 2025年12月19日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2025 年，AAV 基因治療市場價值將達到 34.6 億美元，預計到 2032 年將達到 169.7 億美元，2025 年至 2032 年的複合年成長率為 25.5%。

分析範圍		分析詳情
基準年	2024	市場規模（2025 年）	34.6億美元
效能數據	2020-2024	預測期	2025-2032
預測期（2025-2032 年）複合年成長率	25.50%	預計金額（2032 年）	169.7億美元

全球 AAV 基因治療市場是現代醫學的一個創新領域，它利用腺結合病毒(AAV) 載體作為先進的遞送系統，將治療基因直接輸送到目標細胞中，從而能夠治療各種遺傳性和後天性疾病。

由於其優異的安全性、極低的免疫抗原性以及無需整合到宿主基因組中即可實現持續基因表現的能力，AAV 基因療法已成為一種突破性的治療方法。

這種創新治療方法利用了 AAV 載體的獨特特性，AAV 是一種天然存在的非致病性病毒，經過廣泛的工程改造，消除了其複製能力，同時保留了其將基因轉移到多種組織類型中分裂和非分裂細胞的卓越能力。

該市場涵蓋多種治療應用，包括遺傳性視網膜疾病、血友病、脊髓性肌肉萎縮症和各種中樞神經系統疾病，許多臨床試驗顯示出令人鼓舞的療效。隨著全球監管機構不斷核准基於腺相關病毒（AAV）的基因療法，以及製藥公司加大研發投入，載體工程技術的進步、生產過程的改進以及治療靶點的拓展，使得AAV基因療法成為治療以往無法治癒的遺傳疾病的變革性方案，並推動了市場前所未有的成長。

市場動態

全球AAV基因治療市場受到多種強勁促進因素的影響，這些因素正推動醫療保健產業的蓬勃發展。主要成長要素是全球遺傳性疾病和罕見病患疾病率的不斷上升，以及對以往無法治癒的疾病有效治療方法的迫切需求，從而催生了對創新AAV治療方案的巨大市場需求。

載體工程領域的重要技術進步，特別是新型AAV衣殼的開發，這些衣殼具有更高的組織特異性和更優的轉導效率，極大地拓展了這些治療方法的治療潛力和臨床應用範圍。美國FDA和歐洲藥品管理局（EMA）等監管機構建立的支持性法規結構，特別是罕見疾病藥物的加速核准程序和孤兒藥認定，加速了AAV基因療法的研發進程和市場准入。

然而，該市場面臨著巨大的限制因素，主要是與 AAV 載體生產相關的極高製造成本，這導致治療成本高昂，限制了患者的獲得途徑，並給全球醫療保健系統帶來了報銷方面的挑戰。

此外，潛在的安全隱患，例如AAV載體可能引發免疫抗原性反應和基因毒性，仍然是監管方面的障礙，可能會延緩產品核可和市場滲透。儘管存在這些挑戰，但隨著治療應用範圍從罕見遺傳疾病擴展到心血管疾病、神經退化性疾病疾病和眼科疾病等更常見的疾病，以及懸浮細胞培養系統和新型純化方法等新興生產技術的出現，市場機會依然巨大。這些技術可望降低生產成本並提高規模化生產能力，最終提升市場可及性和成長潛力。

本報告的主要特點

本報告對全球 AAV 基因治療市場進行了詳細分析，並給出了預測期（2025-2032 年）的市場規模和複合年成長率，以 2024 年為基準年。
它還重點介紹了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
它還提供了有關市場促進因素、限制因素和機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的關鍵見解。
全球 AAV 基因治療市場的主要企業將根據以下參數進行分析，例如公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使負責人和公司經營團隊能夠就未來的產品發布、產品更新、市場擴張和行銷策略做出明智的決策。
《全球 AAV 基因治療市場》報告面向該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球 AAV 基因治療市場的各種策略矩陣，更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
中東
- 海灣合作理事會
- 以色列
- 其他中東地區
非洲
- 南非
- 北非
- 中非

第14章競爭格局

Novartis（AveXis）
Spark Therapeutics（Roche）
BioMarin Pharmaceutical
Sarepta Therapeutics
uniQure
Regenxbio
Audentes Therapeutics（Astellas）
Voyager Therapeutics
MeiraGTx
Asklepios BioPharmaceutical（AskBio-Bayer）
Krystal Biotech
Genethon
BridgeBio Gene Therapy
Passage Bio
Solid Biosciences

第15章分析師建議

機會
分析師觀點
Coherent Opportunity Map (COM)

第16章參考文獻與分析方法

參考
分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI9108

AAV Gene Therapy Market is estimated to be valued at USD 3.46 Bn in 2025 and is expected to reach USD 16.97 Bn by 2032, growing at a compound annual growth rate (CAGR) of 25.5% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 3.46 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	25.50%	2032 Value Projection:	USD 16.97 Bn

The global AAV gene therapy market represents a revolutionary frontier in modern medicine, utilizing Adeno-Associated Virus (AAV) vectors as sophisticated delivery systems to transport therapeutic genes directly into target cells for treating various genetic disorders and acquired diseases.

AAV gene therapy has emerged as a groundbreaking therapeutic approach due to its exceptional safety profile, minimal immunogenicity, and ability to achieve long-lasting gene expression without integrating into the host genome.

This innovative treatment modality leverages the unique characteristics of AAV vectors, which are naturally occurring, non-pathogenic viruses that have been extensively engineered to remove their replicative capacity while retaining their remarkable ability to transduce both dividing and non-dividing cells across multiple tissue types.

The market encompasses a diverse range of therapeutic applications including inherited retinal diseases, hemophilia, spinal muscular atrophy, and various central nervous system disorders, with numerous clinical trials demonstrating promising efficacy outcomes. As regulatory agencies worldwide continue to approve AAV-based gene therapies and pharmaceutical companies intensify their research and development efforts, the market is experiencing unprecedented growth driven by technological advancements in vector engineering, improved manufacturing processes, and expanding therapeutic targets that collectively position AAV gene therapy as a transformative solution for previously untreatable genetic conditions.

Market Dynamics

The global AAV gene therapy market is propelled by several compelling drivers that collectively fuel its robust expansion across the healthcare landscape. The primary growth catalyst stems from the increasing prevalence of genetic disorders and rare diseases worldwide, coupled with the urgent unmet medical need for effective treatments in conditions previously deemed incurable, creating substantial market demand for innovative AAV-based therapeutic solutions.

Significant technological advancements in vector engineering, including the development of novel AAV capsids with enhanced tissue specificity and improved transduction efficiency, have dramatically expanded the therapeutic potential and clinical applicability of these treatments. Supportive regulatory frameworks established by agencies such as the U.S. FDA and EMA, including expedited approval pathways for rare disease treatments and orphan drug designations, have accelerated the development timeline and market entry for AAV gene therapies.

However, the market faces notable restraints primarily centered around the exceptionally high manufacturing costs associated with AAV vector production, which translates into substantial treatment expenses that limit patient accessibility and create reimbursement challenges for healthcare systems globally.

Additionally, potential safety concerns including immunogenic responses to AAV vectors and the risk of genotoxicity continue to pose regulatory hurdles that may delay product approvals and market penetration. Despite these challenges, the market presents tremendous opportunities driven by expanding therapeutic applications beyond rare genetic diseases into more prevalent conditions such as cardiovascular diseases, neurodegenerative disorders, and ophthalmologic conditions, while emerging manufacturing technologies including suspension cell culture systems and novel purification methods promise to reduce production costs and improve scalability, ultimately enhancing market accessibility and growth potential.

Key Features of the Study

This report provides in-depth analysis of the global AAV gene therapy market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global AAV gene therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis (AveXis), Spark Therapeutics (Roche), BioMarin Pharmaceutical, Sarepta Therapeutics, uniQure, Regenxbio, Audentes Therapeutics (Astellas), Voyager Therapeutics, MeiraGTx, Asklepios BioPharmaceutical (AskBio - Bayer), Krystal Biotech, Genethon, BridgeBio Gene Therapy, Passage Bio, and Solid Biosciences
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global AAV gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global AAV gene therapy market

Market Segmentation

Vector Serotype Insights (Revenue, USD Bn, 2020 - 2032)
- AAV9
- AAV2
- AAV5
- AAV8
- AAV1
- Engineered/Synthetic AAV Variants
Therapeutic Area Insights (Revenue, USD Bn, 2020 - 2032)
- Neurological Disorders
- Ophthalmic Disorders
- Rare Genetic Disorders
- Hematological Disorders
- Muscular Disorders
- Metabolic Disorders
- Cardiovascular Disorders
- Oncology
- Others
Target Tissue Insights (Revenue, USD Bn, 2020 - 2032)
- Central Nervous System
- Eye/Retina
- Liver
- Muscle
- Lung
- Heart
- Blood/Bone Marrow
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Intravenous
- Intrathecal
- Intracerebral
- Subretinal
- Intravitreal
- Intramuscular
- Intracardiac
Indication Type Insights (Revenue, USD Bn, 2020 - 2032)
- Monogenic Disorders
- Polygenic Disorders
Gene Payload Type Insights (Revenue, USD Bn, 2020 - 2032)
- Gene Replacement
- Gene Silencing
- Gene Augmentation
Development Stage Insights (Revenue, USD Bn, 2020 - 2032)
- Preclinical
- Phase I
- Phase II
- Phase III
Manufacturing Type Insights (Revenue, USD Bn, 2020 - 2032)
- In-house Manufacturing
- Contract Manufacturing (CDMO/CMO)
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Biopharmaceutical Companies
- Research Institutes and Academic Centers
- Hospitals and Specialty Clinics
- Others (CROs)
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novartis (AveXis)
- Spark Therapeutics (Roche)
- BioMarin Pharmaceutical
- Sarepta Therapeutics
- uniQure
- Regenxbio
- Audentes Therapeutics (Astellas)
- Voyager Therapeutics
- MeiraGTx
- Asklepios BioPharmaceutical (AskBio - Bayer)
- Krystal Biotech
- Genethon
- BridgeBio Gene Therapy
- Passage Bio
- Solid Biosciences

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global AAV Gene Therapy Market, By Vector Serotype
- Global AAV Gene Therapy Market, By Therapeutic Area
- Global AAV Gene Therapy Market, By Target Tissue
- Global AAV Gene Therapy Market, By Route of Administration
- Global AAV Gene Therapy Market, By Indication Type
- Global AAV Gene Therapy Market, By Gene Payload Type
- Global AAV Gene Therapy Market, By Development Stage
- Global AAV Gene Therapy Market, By Manufacturing Type
- Global AAV Gene Therapy Market, By End User
- Global AAV Gene Therapy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global AAV Gene Therapy Market, By Vector Serotype, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
AAV9
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
AAV2
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
AAV5
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
AAV8
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
AAV1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Engineered/Synthetic AAV Variants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global AAV Gene Therapy Market, By Therapeutic Area, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ophthalmic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Rare Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hematological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Muscular Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Metabolic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cardiovascular Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global AAV Gene Therapy Market, By Target Tissue, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Central Nervous System
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Eye/Retina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Liver
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Muscle
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Lung
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Heart
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Blood/Bone Marrow
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global AAV Gene Therapy Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intrathecal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intracerebral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Subretinal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intravitreal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intracardiac
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global AAV Gene Therapy Market, By Indication Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Monogenic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Polygenic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global AAV Gene Therapy Market, By Gene Payload Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Gene Replacement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Gene Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Gene Augmentation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global AAV Gene Therapy Market, By Development Stage, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Preclinical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Phase I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Phase II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Phase III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global AAV Gene Therapy Market, By Manufacturing Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
In-house Manufacturing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Contract Manufacturing (CDMO/CMO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global AAV Gene Therapy Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Biopharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Research Institutes and Academic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hospitals and Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

13. Global AAV Gene Therapy Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

14. Competitive Landscape

Novartis (AveXis)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Spark Therapeutics (Roche)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BioMarin Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sarepta Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
uniQure
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Regenxbio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Audentes Therapeutics (Astellas)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Voyager Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
MeiraGTx
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Asklepios BioPharmaceutical (AskBio - Bayer)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Krystal Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Genethon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BridgeBio Gene Therapy
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Passage Bio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Solid Biosciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies